InflaRx N.V. (IFRX)
IFRX Stock Price Chart
Explore InflaRx N.V. interactive price chart. Choose custom timeframes to analyze IFRX price movements and trends.
IFRX Company Profile
Discover essential business fundamentals and corporate details for InflaRx N.V. (IFRX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
7 Nov 2017
Employees
74.00
Website
https://www.inflarx.deCEO
Niels C. Riedemann
Description
InflaRx N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel inhibitors leveraging C5a technology, primarily operating in Germany and the United States. The company's focus on C5a stems from its critical role as an inflammatory mediator implicated in the progression of various autoimmune and inflammatory diseases. Its primary product candidate, vilobelimab, is an innovative, first-in-class anti-C5a monoclonal antibody delivered intravenously. Vilobelimab has progressed through several clinical stages for multiple indications: It has successfully completed a Phase III clinical trial for hidradenitis suppurativa (HS), a rare, chronic, and debilitating systemic inflammatory skin condition. It is currently undergoing Phase II trials for anti-neutrophil cytoplasm antibody associated vasculitis (AAV), a rare and life-threatening autoimmune disorder, and for PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC). An exploratory Phase IIa study is also underway for pyoderma gangraenosum (PG), a chronic inflammatory skin disorder. Beyond its lead candidate, InflaRx is also advancing INF904, an oral, small molecule drug candidate targeting undisclosed chronic inflammatory and autoimmune diseases, and IFX002, which is in preclinical development for chronic inflammation and autoimmune conditions. Strategic collaborations include a co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. and a clinical trial collaboration and supply agreement with Merck & Co. Inc. Established in 2007, the company, initially known as Fireman B.V., officially became InflaRx N.V. in 2017. It maintains its headquarters in Jena, Germany, with operations extending to the United States.
IFRX Financial Timeline
Browse a chronological timeline of InflaRx N.V. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.08, while revenue estimate is $6.40k.
Earnings released on 7 May 2026
EPS came in at -$0.09 surpassing the estimated -$0.17 by +47.06%.
Earnings released on 19 Mar 2026
EPS came in at -$0.17 surpassing the estimated -$0.18 by +5.56%, while revenue for the quarter reached -$17.62k , missing expectations by -164.52%.
Earnings released on 10 Nov 2025
EPS came in at -$0.16 matching the estimated -$0.16, while revenue for the quarter reached $27.91k , beating expectations by +6.65%.
Earnings released on 7 Aug 2025
EPS came in at -$0.24 matching the estimated -$0.24, while revenue for the quarter reached $46.43k , beating expectations by +78.57%.
Earnings released on 7 May 2025
EPS came in at -$0.14 surpassing the estimated -$0.18 by +22.22%.
Earnings released on 20 Mar 2025
EPS came in at -$0.09 surpassing the estimated -$0.27 by +66.67%, while revenue for the quarter reached -$438.01 , missing expectations by -100.93%.
Earnings released on 8 Nov 2024
EPS came in at -$0.33 falling short of the estimated -$0.27 by -22.22%, while revenue for the quarter reached $135.80k , beating expectations by +1.85%.
Earnings released on 8 Aug 2024
EPS came in at -$0.26 falling short of the estimated -$0.21 by -23.81%, while revenue for the quarter reached $6.84k , missing expectations by -92.41%.
Earnings released on 8 May 2024
EPS came in at -$0.19 surpassing the estimated -$0.24 by +20.83%, while revenue for the quarter reached $38.71k , missing expectations by -97.15%.
Earnings released on 21 Mar 2024
EPS came in at -$0.30 falling short of the estimated -$0.20 by -50.00%, while revenue for the quarter reached $2.51k , missing expectations by -99.82%.
Earnings released on 1 Nov 2023
EPS came in at -$0.14 surpassing the estimated -$0.29 by +51.72%, while revenue for the quarter reached $64.14k , missing expectations by -97.02%.
Earnings released on 10 Aug 2023
EPS came in at -$0.15 surpassing the estimated -$0.36 by +58.33%.
Earnings released on 11 May 2023
EPS came in at -$0.27 surpassing the estimated -$0.30 by +10.00%.
Earnings released on 22 Mar 2023
EPS came in at -$0.18 falling short of the estimated $0.25 by -172.00%.
Earnings released on 9 Nov 2022
EPS came in at -$0.18 surpassing the estimated -$0.36 by +50.00%.
Earnings released on 5 Aug 2022
EPS came in at $0.01 surpassing the estimated -$0.34 by +102.94%.
Earnings released on 12 May 2022
EPS came in at -$0.36 falling short of the estimated -$0.34 by -5.88%.
Earnings released on 24 Mar 2022
EPS came in at -$0.33 surpassing the estimated -$0.37 by +10.81%.
Earnings released on 5 Nov 2021
EPS came in at -$0.32 surpassing the estimated -$0.37 by +13.51%.
Earnings released on 5 Aug 2021
EPS came in at -$0.40 falling short of the estimated -$0.25 by -60.00%.
IFRX Stock Performance
Access detailed IFRX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
